Uniphore Unveils Enhanced Interaction Analytics Solution Powered by Generative AI
21.3.2024 16:41:00 EET | Business Wire | Press release
Uniphore, one of the world’s largest AI-native companies, announced a major upgrade to its U-Analyze analytics solution, which builds on the company’s industry-leading multimodal enterprise AI platform to help customers effectively access data and power their AI needs.
This new generative AI-fueled version of U-Analyze directly addresses a growing need among global enterprises to leverage the power of AI and their own data. Drawing from customer conversations across text, voice and video, business leaders can make knowledgeable, timely, data-driven decisions to revolutionize their customers’ experiences as well as agent performance.
This announcement is a deliberate next step following the introduction of Uniphore’s groundbreaking U Capture, an AI-native solution that aids customers’ ability to capture, structure and apply a full suite of multimodal data --- powered by the company’s X-Platform. A key benefit for customers includes the ownership and accessibility of their own data whenever they need it, to drive additional value.
Bolstered by Uniphore’s powerful X-Platform, U-Analyze works seamlessly with U-Capture to analyze conversational data in real time and generate unique AI-driven insights for each enterprise. The insights, along with the automated and manual coaching capabilities, allow enterprises to continuously improve customer experiences and engagement. Ultimately, U-Analyze will help enterprises predict and adapt to customer and market needs.
When you combine the power of the two solutions, the analytics provide timely AI-generated insights that have the potential to dramatically improve customer satisfaction and engagement.
“Analytics will never be the same with Uniphore’s enterprise-grade AI platform transforming the way our customers are able to harness the power and value of data,” said Umesh Sachdev, CEO and Co founder of Uniphore. “This is a significant milestone in Uniphore’s unwavering commitment to our global enterprise customers on their journey to becoming AI-led companies.”
A recent global survey of over 500 contact center leaders sponsored by Uniphore underscored the need for AI-driven insights. For example, nearly 40% of respondents said they lack the data to respond quickly to business decisions or improve their customers’ experiences. Also, 86% said the decisions they make are not predominantly data-driven, reinforcing the massive opportunity for business leaders and enterprises to put their own data to use.
“Enterprise organizations are hungry for better insights – and better conversational analytics solutions. Traditional analytics solutions don’t necessarily include the technologies driving the current wave of innovation in the enterprise – including generative AI and knowledge AI,” said Hayley Sutherland, Research Manager, Conversational AI & Intelligent Knowledge Discovery at IDC. “With these upgrades to U-Analyze, Uniphore is keeping on the cutting edge of such innovations and helping organizations move the needle when it comes to AI-driven actionable insights based on customer interactions, which could have a big impact on business processes and results.”
Uniphore will be at Enterprise Connect at the Gaylord Palms in Orlando, Florida from March 25-28, 2024 at booth 306 in the AI Innovation Zone.
For additional information on the U and Q product lines, please click here.
To stay up to date with the latest commentary, follow our blog, or connect with us on LinkedIn, X, Facebook, or Instagram.
About Uniphore
Uniphore is one of the largest B2B AI-native companies – decades-proven, built-for-scale, and designed for the Enterprise. The company drives business outcomes, across multiple industry verticals, and the largest global deployments. Uniphore infuses AI into every part of the Enterprise that impacts the customer. We deliver the only multimodal AI architecture centered on customers that combines Generative AI, Knowledge AI and Emotion AI and Workflow Automation and a co-pilot to guide you. We understand better than anyone how to capture voice, video, text, and how to analyze all types of data. As AI becomes more powerful, every part of the Enterprise that impacts the customer will be disrupted. We believe the future will run on the connective tissue between people, machines and data: all in service of creating the most human processes and experiences for customers and employees.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321078876/en/
Contact information
For more information, please contact: pr@uniphore.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom